About: Sang Hoon Ahn

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sang Hoon Ahn Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

South Korean gastroenterologist

Attributes	Values
rdf:type	Item
field of work	wds:Q63436666-1F781E06-1319-4660-B014-E0B8BA4114F8
field of work	chronic hepatitis B
description	forskare (sv) ikertzailea (eu) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) изилдөөчү (ky) հետազոտող (hy) South Korean gastroenterologist (en) 연세대학교 의과대학 소화기내과 교수, 간염 연구 권위자 (ko)
rdfs:label	안상훈 (ko) Sang Hoon Ahn (en) Sang Hoon Ahn (es) Sang Hoon Ahn (nl) Sang Hoon Ahn (ast)
skos:prefLabel	안상훈 (ko) Sang Hoon Ahn (en) Sang Hoon Ahn (es) Sang Hoon Ahn (nl) Sang Hoon Ahn (ast)
name	안상훈 (ko) Sang Hoon Ahn (en) Sang Hoon Ahn (es) Sang Hoon Ahn (nl) Sang Hoon Ahn (ast)
given name	wds:Q63436666-757CF503-4FF3-4BCC-B760-CCD156788A34
given name	Sang-hun
instance of	wds:Q63436666-E8B3A745-4E4A-4DDF-9148-9200B5917D32
instance of	Homo sapiens
K-Scholar ID	wds:Q63436666-21C04D84-F569-48D9-8F45-FDC8E97B19EB
K-Scholar ID	P2014195355
occupation	wds:Q63436666-7BAE0A05-0524-48F4-B22D-AFDC785039F2
employer	wds:Q63436666-46A29455-0E7D-4752-A707-1138165298AD wds:Q63436666-9A95F16D-24AA-49AF-B510-373C129CD2EE
sex or gender	wds:Q63436666-272EFD69-EE80-434F-A6B9-654AB19E21F1
ISNI	wds:Q63436666-823AF9F5-8F48-40DA-B2CE-9CFDF4686232
VIAF ID	wds:Q63436666-7A782575-C275-4B55-BDBF-EE63CE6EA8D7
country of citizenship	wds:Q63436666-E3804F8E-309D-4837-8E15-7AE7DA89C416
National Library of Korea ID	wds:Q63436666-2D94D13A-F1F9-4CA2-A1FF-36ED323D46E0
date of birth	wds:Q63436666-289B5104-3CF5-4D2A-80B9-21FD9260EB0D
family name	wds:Q63436666-7E8B45BC-7F44-4100-99A2-D01C50D70805
VIAF ID	http://viaf.org/viaf/24152138530310981151
National Library of Korea ID	http://lod.nl.go.kr/resource/KAC201803528
occupation	researcher
employer	Yonsei University Health System Yonsei University College of Medicine
sex or gender	male
ISNI	0000000464332207
VIAF ID	24152138530310981151
country of citizenship	Korea
National Library of Korea ID	KAC201803528
date of birth	1970-01-01 00:00:00Z (xsd:dateTime)
family name	Ahn
ORCID iD	wds:Q63436666-F61A9CB9-BBDD-49ED-8567-292543B81C66
ORCID iD	https://orcid.org/0000-0002-3629-4624
ORCID iD	0000-0002-3629-4624
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q63436666
is author of	MRP2 haplotypes confer differential susceptibility to toxic liver injury Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Emerging therapies for hepatitis C Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. Clinical features and treatment outcomes of upper gastrointestinal bleeding in patients with cirrhosis. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Transient elastography in chronic hepatitis B: an Asian perspective. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients Long-term outcome of chronic hepatitis B based on histological grade and stage. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software